Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 17, 2015
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow TransplantationMiguel-Angel Perales, Izaskun Ceberio, Philippe Armand, et al.
American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
The Oncologist|May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelDouglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
American Journal of Clinical Pathology|October 15, 2013
Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approachAdam C Seegmiller, Annette S Kim, Claudio A Mosse, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
British Journal of Haematology|July 30, 2016
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiableDaniel J Landsburg, Marissa K Falkiewicz, Adam M Petrich, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Cancer|February 14, 2022
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 studyPallawi Torka, Othman S Akhtar, Nishitha M Reddy, et al.
Pageof 4